Immunic Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2012
Selling, General & Admin	16.01	15.26	30.55	10.33	14.52	Upgrade
Research & Development	83.22	71.26	61.12	38.64	22.51	Upgrade
Other Operating Expenses	0	32.97	0	0	0	Upgrade
Operating Expenses	99.22	119.49	91.67	48.97	37.03	Upgrade
Operating Income	-99.22	-119.49	-91.67	-48.97	-37.03	Upgrade
Other Expense / Income	-5.61	0.92	1.28	-4.95	-2.1	Upgrade
Pretax Income	-93.61	-120.41	-92.95	-44.02	-34.93	Upgrade
Net Income	-93.61	-120.41	-92.95	-44.02	-34.93	Upgrade
Shares Outstanding (Basic)	44	32	24	16	8	Upgrade
Shares Outstanding (Diluted)	44	32	24	16	8	Upgrade
Shares Change	39.29%	34.53%	51.00%	102.84%	811.77%	Upgrade
EPS (Basic)	-2.11	-3.78	-3.93	-2.81	-4.52	Upgrade
EPS (Diluted)	-2.11	-3.78	-3.93	-2.81	-4.52	Upgrade
Free Cash Flow	-71.16	-65.26	-83.3	-46.27	-28.56	Upgrade
Free Cash Flow Per Share	-1.61	-2.05	-3.52	-2.95	-3.70	Upgrade
EBITDA	-93.5	-120.33	-92.86	-43.98	-34.88	Upgrade
Depreciation & Amortization	0.11	0.08	0.09	0.04	0.05	Upgrade
EBIT	-93.61	-120.41	-92.95	-44.02	-34.93	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).